In addition, this potential TGF-β function highlights the relevance of clearly determining which patients should be submitted to TGF-β inhibitors and considering probable poor outcomes for post-operative patients or patients with cancer in advanced stage (Figure 1). The gene discussed is TGFB1; the disease is cancer.